Also, given that the guideline recommendation is mainly based on this one large study (level of evidence IB),15, 81 there is certainly sufficient evidence to also treat patients with AF and HFrEF who are symptomatic on ACE inhibitors with sacubitril/valsartan to reduce morbidity and mortality. This evidence concerns the gene ACE and atrial fibrillation.